Calcium gluconate
Essential systemic electrolyte indicated for acute hypocalcemic emergencies and immediate membrane stabilization during severe hyperkalemia. Competitively blocks cellular toxicity without shifting serum potassium.
Physiological mechanisms of elemental calcium
Calcium Gluconate delivers bioavailable ionized calcium (Ca²⁺) to restore cellular homeostasis, stabilize excitable myocardial tissue, and antagonize electrolyte toxicity.
Primary physiological pathways
Systemic biological roles of ionized calcium in acute and maintenance pharmacotherapy
- Maintains the cardiac action potential plateau phase (Phase 2) through L-type calcium channels.
- Stabilizes resting membrane threshold potential to counteract potassium-induced depolarization.
- Supports myocardial contractility (inotropy) and automaticity in nodal pacemakers.
- Triggers neurotransmitter vesicle fusion and acetylcholine release at the neuromuscular junction.
- Regulates voltage-gated sodium channel thresholds to suppress peripheral nerve hyper-excitability.
- Prevents hypocalcemic tetany, paresthesias, and spontaneous latent spasms (Trousseau/Chvostek).
- Binds directly to troponin C, inducing conformational shifts that expose active actin binding sites.
- Mediates intracellular calcium transient cycling via sarcoplasmic reticulum RyR2 receptors.
- Regulates tone in vascular smooth muscle and ensures synchronized skeletal muscle contraction.
- Serves as the structural mineral backbone of crystalline hydroxyapatite [Ca₁₀(PO₄)₆(OH)₂].
- Functions as essential Factor IV in intrinsic and extrinsic coagulation cascades for prothrombin activation.
- Acts as a tightly buffered intracellular secondary messenger across vascular and endocrine tissue.
Emergency antidote mechanisms
Targeted electrophysiological interventions in hyperkalemia and magnesium overdose
Verify IV push rates and administration guidelines prior to hyperkalemia or hypocalcemia intervention. Slow IV rate limit: ≤200 mg/min in adults.
Primary therapeutic indications
Bedside therapeutic pathways and calibrated dosing parameters for Calcium Gluconate administration across acute, emergency, and maintenance protocols.
Restoration of ionized serum calcium deficits secondary to hypoparathyroidism, vitamin D deficiency, osteomalacia, and rickets.
Immediate alleviation of severe neuromuscular excitability, carpopedal spasm, Chvostek's/Trousseau's signs, and hypocalcemia-triggered seizures.
Cardiac Protection in Hyperkalemia
Direct myocardial cell membrane stabilization to counteract hyperkalemia-induced cardiotoxicity and peaked T-wave conduction delays without lowering serum K+.
Competitive antagonism to reverse life-threatening hypermagnesemia, respiratory depression, and severe neuromuscular blockade from magnesium tocolysis/eclampsia therapy.
Citrate toxicity mitigation during rapid massive blood exchange transfusions and secondary inotropic support in calcium channel blocker toxicity.
Absolute clinical prohibitions & safety barriers
Calcium gluconate requires strict adherence to administration boundaries. Verify baseline serum parameters, concurrent drug regimens, and patient age before initiating IV therapy.
Never administer intramuscularly (IM) or subcutaneously (SubQ)
Intravenous infusion is the only approved parenteral route. Direct tissue infiltration via IM or SubQ routes results in severe local tissue irritation, deep calcinosis cutis, excruciating chemical burns, and progressive tissue sloughing leading to permanent necrotic ulceration.
Hypercalcemia
Absolute prohibition
Pre-existing hypercalcemia of any origin or vitamin D toxicity. Exogenous calcium administration triggers acute hypercalcemic crisis, vascular calcification, and irreversible cardiac arrest.
Concurrent Digoxin Therapy
Cardiac glycoside synergy
Concurrent administration with cardiac glycosides causes synergistic myocardial toxicity. Calcium ions enhance digitalis-induced intracellular calcium overload, precipitating refractory ventricular arrhythmias and heart block.
Ventricular Fibrillation
Arrest protocol restriction
Prohibited during standard cardiac resuscitation in the presence of ventricular fibrillation, except when secondary to severe documented hyperkalemia or calcium channel blocker overdose.
Neonatal Ceftriaxone Incompatibility
Ages ≤ 28 days
Strictly contraindicated in neonates (≤ 28 days old) receiving IV ceftriaxone, even via separate infusion lines. Risk of fatal crystalline calcium-ceftriaxone precipitates in lungs and kidneys.
Severe Renal Impairment & Lithiasis
End-stage renal disease / Stones
High-risk caution in end-stage renal disease and history of calcium nephrolithiasis or severe hypercalciuria. Impaired clearance leads to acute calcium retention and systemic calciphylaxis.
Clinical Mandate: In the event of suspected extravasation or acute bradycardia during bolus, stop infusion immediately and notify the attending physician.
System-by-system adverse reactions & complications
Comprehensive monitoring protocols and clinical manifestations across major organ systems, distinguishing rate-dependent infusion risks from systemic electrolyte toxicities.
Elemental Calcium Yield
93 mg Ca²⁺ / 10 mL
Equivalent to 4.65 mEq elemental calcium in 10% solution.
Maximum IV Infusion Rate
≤ 200 mg / min
Slow IV infusion over 10–20 min; 0.5–1.0 mL/min prevents bradycardia.
Route Absolute Prohibition
NEVER IM or SubQ
Severe tissue necrosis and calcinosis cutis will occur.
Calcium Gluconate Extravasation & Tissue Injury Pathway
Calcium extravasation triggers rapid calcium-binding in soft tissues, causing calcinosis and progressive ischemia. Execute the following sequence without delay:
Halt infusion immediately
Stop pump at the first sign of erythema, swelling, or patient-reported burning.
Aspirate residual drug
Leave cannula in place; attach 3 mL syringe to gently aspirate extravasated fluid.
Hyaluronidase protocol
Inject 150–300 units intradermally/subcutaneously around the affected periphery.
Elevate & apply compress
Elevate extremity; apply warm or cold compress per institutional policy.
Clinical administration timeline
A chronological four-stage delivery workflow for Calcium Gluconate (10% IV solution). Follow strict rate boundaries, vascular checks, and continuous telemetry at each phase.
10% Calcium Gluconate Injection
100 mg/mL Solution
93 mg Ca²⁺ (4.65 mEq)
Per 10 mL single-dose vial
≤ 200 mg/min (2 mL/min)
Slow IV push or infusion
NEVER give IM or SubQ
Severe tissue sloughing risk
Clinical Action Checklist
- Confirm peripheral IV line or central access patency with a normal saline flush to prevent extravasation risk.
- Document baseline ionized calcium (1.16–1.32 mmol/L), serum magnesium, potassium, and renal panel.
- Assess for clinical signs of hypocalcemia (positive Chvostek's or Trousseau's sign, acute tetany, paresthesias).
- Record baseline blood pressure and baseline 12-lead ECG telemetry trace.
Clinical Action Checklist
- Adult acute hypocalcemia: administer 1–2 g (10–20 mL of 10% solution) slowly over 10–20 minutes.
- Hyperkalemia cardiac stabilization: deliver 1 g slow IV over 2–5 minutes under direct physician supervision.
- Strict infusion velocity limit: never exceed 200 mg/min in adults or 100 mg/min in pediatric patients.
- Inspect insertion site continuously for localized blanching, burning, swelling, or signs of chemical extravasation.
Clinical Action Checklist
- Maintain continuous lead II/V5 cardiac rhythm monitoring during and immediately following any IV bolus.
- Watch for resolution of peaked T-waves, widening QRS complexes, or sine-wave patterns in severe hyperkalemia.
- Monitor for QT interval shortening and acute onset of sinus bradycardia or junctional escape rhythms.
- Re-evaluate concurrent cardiac glycoside therapy; absolute caution required in patients taking digoxin.
Clinical Action Checklist
- Draw repeat serum calcium and ionized Ca²⁺ levels at 4- to 6-hour post-infusion milestones.
- Reassess serum potassium and renal function panels (BUN, creatinine) to guide repeat dosing regimens.
- Examine patient for hypercalcemia symptoms: acute nausea, metallic taste, severe thirst, or altered sensorium.
- Transition stable patients to scheduled oral maintenance therapy (1–2 g elemental calcium daily with meals).
Immediate Infusion Cessation Criteria
Promptly terminate calcium gluconate administration if any of the following acute physiological triggers occur at the bedside:
Acute Bradycardia or Arrhythmia
Halt infusion immediately if heart rate drops significantly or sudden QT shortening/ectopy appears on monitor.
Peripheral Extravasation
Stop IV immediately at any report of localized burning or visible swelling. Aspirate residual drug and apply cold compress.
Severe Hypotension or Flushing
Pause flow and verify vital signs. Infusing too rapidly causes peripheral vasodilation and sudden arterial pressure collapse.
Review Full Nursing Protocols
Detailed dilution guides, compatibility tables, and patient discharge teaching.
Clinical parameter anchor (10% solution)
93 mg elemental Ca²⁺ (4.65 mEq) per 10 mL vial
Quick dosing protocols
Use verified elemental concentrations and slow IV infusion parameters to prevent severe bradycardia, hypotension, and cardiac arrest.
Extravasation prevention
Verify vein patency prior to administration. Infiltration causes severe calcinosis and local tissue necrosis. Halt infusion immediately if swelling or burning occurs.